Samsrita Labs Ltd. (SAMSRITA) — Tipsheet https://tipsheet.markets/company/samsrita/ Every Tipsheet Editorial note covering Samsrita Labs Ltd. (SAMSRITA), newest first. Grounded in BSE/NSE primary-source filings. en-in Tue, 28 Jul 2026 14:38:35 GMT Samsrita Labs to cancel half its shares, wipe out ₹11.37 cr in losses https://tipsheet.markets/samsrita-samsrita-labs-to-cancel-half-its-shares-wipe-out-11-37-cr-in-losses-119160/ https://tipsheet.markets/samsrita-samsrita-labs-to-cancel-half-its-shares-wipe-out-11-37-cr-in-losses-119160/ Sat, 04 Jul 2026 16:23:52 GMT The capital reduction cuts paid-up capital from ₹22.75 cr to ₹11.37 cr, setting off all accumulated losses and share premium. The move, equal to 42% of market cap, cleans the balance sheet ahead of a pet healthcare pivot. The capital reduction cuts paid-up capital from ₹22.75 cr to ₹11.37 cr, setting off all accumulated losses and share premium. The move, equal to 42% of market cap, cleans the balance sheet ahead of a pet healthcare pivot.

What’s new

  • Board approves 1:2 share cancellation, cutting paid-up capital in half.
  • ₹11.37 cr in accumulated losses and entire share premium extinguished.
  • New non-executive director with 7.1% stake and fundraising expertise appointed.

Why it matters

For a ₹28 cr nano-cap with a negative net worth, this balance sheet reset eliminates the biggest drag on equity. If approved, it leaves Samsrita with a positive net worth and a clean slate for the pet healthcare pivot.

What we’re watching

  • NCLT and shareholder approval timelines for the scheme.
  • Whether a follow-on fundraise or business deal materialises post-restructuring.
  • Execution of the pet animal healthcare business added to the memorandum.

The full read

Samsrita Labs is cancelling half of its equity shares (1,13,74,855 shares of ₹10 each) to write off ₹11.37 crore in accumulated losses and the entire share premium balance. The pro-rata cancellation reduces paid-up capital from ₹22.75 crore to ₹11.37 crore but leaves ownership percentages untouched and pays no cash. For a company with a market cap of just ₹28 crore and a negative net worth, this is a balance sheet reset that could transform its financial health. The board also appointed a funding specialist with a 7.1% stake as a director and amended the memorandum to formally include pet animal healthcare, confirming the strategic pivot announced earlier. None of this is final yet: shareholders and the Hyderabad NCLT must approve the scheme. If they do, Samsrita will emerge with a clean balance sheet, a positive net worth, and a clearer story for capital raising.

Primary source: BSE · NSE

]]> Other Tipsheet Editorial Samsrita Labs board to mull capital rejig; share cancellation on table? https://tipsheet.markets/samsrita-samsrita-labs-board-to-mull-capital-rejig-share-cancellation-on-table-116451/ https://tipsheet.markets/samsrita-samsrita-labs-board-to-mull-capital-rejig-share-cancellation-on-table-116451/ Mon, 29 Jun 2026 18:48:46 GMT The nano-cap healthcare firm, with no operating revenue and Rs 11 cr in losses, will meet on 4 July. Prior reports point to a share cancellation to wipe out accumulated losses. The nano-cap healthcare firm, with no operating revenue and Rs 11 cr in losses, will meet on 4 July. Prior reports point to a share cancellation to wipe out accumulated losses.

What’s new

  • Board to meet on 4 July to consider a draft scheme of share capital reorganisation.
  • No details on whether it's capital reduction, consolidation or fresh issuance.
  • Trading window closed from 30 June until 48 hours after meeting result.

Why it matters

Samsrita Labs has zero operating revenue and negative reserves. A clean-up via share cancellation would remove the accumulated losses from its books, making the balance sheet attractive for potential fundraising or a reverse merger. The market cap of Rs 28 cr suggests the cancellation ratio will be material.

What we’re watching

  • Whether the board approves a straight share cancellation or a more complex restructuring.
  • Any announcement of fresh fundraising or business revival plan alongside the scheme.
  • Stock price reaction given the 28 cr market cap and speculative interest.

The full read

Samsrita Labs, a Hyderabad-based nano-cap with no operating revenue and accumulated losses of Rs 11 crore, is weighing a capital restructuring. The board meets on 4 July to consider a draft scheme—prior coverage points to a share cancellation that would wipe out the losses. The company has not detailed the plan, leaving room for a consolidation or fresh issue, but the logic is clear: with a market cap of Rs 28 crore and negative net worth, any clean-up would make the balance sheet usable again. The trading window is shut from 30 June. The real news will come on 4 July, when the board decides whether to cancel half the shares or pursue a different route.

Primary source: BSE · NSE

]]> Other Tipsheet Editorial